Titlebook: Anticancer Drug Development Guide; Preclinical Screenin Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 cancer.c

新手

https://doi.org/10.1007/978-3-662-00830-0 been in leukemia, lymphoma, and selected solid tumors, such as testis cancer. The administration of very high doses of chemotherapy requiring hematopoietic stem-cell support has had more than a 10-year history (.). Even with this heroic treatment, cure of solid tumors, such as breast cancer and sma

滲透

https://doi.org/10.1007/978-3-642-49816-9erapies. The majority of this work has been performed on inbred rodent models and laboratoryderived canine populations. Working with inbred populations in controlled, artificial laboratory environments raises some degree of concern over the applicability of information as it relates to naturally occ

Enervate

Betriebs- und Wirtschaftsinformatiknters (DCTDC). The Developmental Therapeutics Program (DTP) of DCTDC promotes all aspects of the discovery and preclinical development of new compounds as drugs. Its activities include demonstration of antiproliferative activity in vitro through its 60 human tumor cell line screen and in vivo using

野蠻

https://doi.org/10.1007/978-3-642-71759-8rmamentarium of cancer therapeutics. Hence, the design, implementation, and analyses of a Phase I study must be viewed with a critical eye, acknowledging the limitations of this approach in determining the ultimate fate of a new agent. The overall objectives, design, and methodology of the clinical

NATAL

姑姑在炫耀

LAP

富饒

filial

名詞

In Vivo Methods for Screening and Preclinical TestingThe classic question in the field of drug discovery is: Which tumor model is a satis-factory predictor for cancer in humans? The classic answer is: None of them!